Why not a 95-95-95 strategy for influenza by 2030?

類似資料

• Real-world effectiveness of live attenuated influenza vaccines (LAIV) and inactivated influenza vaccines (IIV) in children from 2003 to 2023: a systematic literature review and network meta-analysis
  著者:: Anke L. Stuurman, 等
  出版事項: (2025-12-01)
• Expert opinion on improving influenza vaccination coverage rate in Qatar: Strategic solutions and role of live attenuated influenza vaccine (LAIV)
  著者:: Muna Al-Maslamani, 等
  出版事項: (2026-12-01)
• Impact of Pre-Existing Immunity to Influenza on Live-Attenuated Influenza Vaccine (LAIV) Immunogenicity
  著者:: Sreeja Roy, 等
  出版事項: (2020-11-01)
• Immunogenicity and Safety of One versus Two Doses of Quadrivalent Inactivated Influenza Vaccine (IIV4) in Vaccine-Unprimed Children and One Dose of IIV4 in Vaccine-Primed Children Aged 3–8 Years
  著者:: Yunfeng Shi, 等
  出版事項: (2023-10-01)
• Inactivated recombinant influenza vaccine: the promising direction for the next generation of influenza vaccine
  著者:: Hua Shi, 等
  出版事項: (2024-12-01)